Yellow Fungus Disease (Nannizziopsis guarroi) in Bearded Dragons

Bottom line

Yellow fungus disease (YFD) in bearded dragons is a contagious, invasive dermatomycosis caused by Nannizziopsis guarroi, a true primary keratinophilic pathogen (order Onygenales) that fulfils Koch's postulates — not a secondary contaminant [1]. Definitive diagnosis is fungal culture plus histopathology showing hyphae invading tissue, with species-level PCR for confirmation; rule out simple dysecdysis, thermal burns, and bacterial dermatitis [2]. First-line systemic therapy is voriconazole 10 mg/kg PO q24h [3] or terbinafine 20 mg/kg PO q24–48h [4], paired with surgical debridement, husbandry correction, and strict quarantine because the fungus seeds the environment before lesions even appear [5]. Prognosis is fair with early, superficial disease but guarded once infection extends to subcutis, bone, or viscera [2].

The pathogen

Nannizziopsis guarroi is the confirmed cause of YFD in bearded dragons. It was historically lumped under "CANV" — the Chrysosporium anamorph of Nannizziopsis vriesii — a catch-all label applied before molecular tools separated the reptile pathogens into distinct species. Sequencing of the ITS and nuclear ribosomal genes reassigned these isolates to the genera Nannizziopsis, Paranannizziopsis, and Ophidiomyces, all within the order Onygenales; the bearded-dragon pathogen is N. guarroi, and the term CANV should be retired [6]. In the Merck Veterinary Manual these organisms sit in the family Nannizziopsiaceae and are recognised as a major dermatologic concern in squamates [2].

Unlike the opportunistic molds (Aspergillus, Fusarium, Mucor) that colonise debilitated or immunosuppressed reptiles, members of the former CANV complex are primary, contagious pathogens: they invade the intact keratinised skin of otherwise healthy hosts [1]. Gentry and colleagues satisfied Koch's postulates by reproducing YFD experimentally, watching lesions progress from raised white bumps to crusty, yellow, discoloured scales and eventual necrosis [1]. Transmission is both direct animal-to-animal and environmental — viable N. guarroi has been cultured from enclosure substrate 7–28 days before clinical lesions appeared in exposed dragons, so an apparently healthy carrier can seed a collection long before it looks sick [5].

Clinical signs

Early lesions are subtle: focal white-to-yellow crusts, roughened or discoloured scales, and thickened hyperkeratotic plaques that resemble retained shed. As infection advances, scales turn yellow-brown, crust, and slough, exposing ulcerated, necrotic dermis; lesions commonly begin on the head, limbs, tail base, or ventrum and coalesce [1]. Because the fungus is keratinophilic and invasive it does not stay superficial — deeper extension into subcutaneous tissue, muscle, bone, and viscera is common, and disseminated disease carries high fatality [2]. Affected dragons are frequently presented for dysecdysis-like crusting, weight loss, lethargy, and inappetence; the discolouration and failure to resolve with a routine shed are what should raise suspicion of YFD over a simple shedding problem.

Diagnosis

Definitive diagnosis rests on three legs: fungal culture, histopathology, and PCR. Culture (e.g., on Sabouraud dextrose agar) recovers the organism, but because keratinophilic fungi can also be surface contaminants, culture alone is not proof of disease [2]. Histopathology of a lesion biopsy is the discriminator — demonstrating fungal hyphae invading viable tissue with an associated host inflammatory (heterophilic/granulomatous) response confirms a true pathogen rather than a colonising contaminant [2]. Species-level identification should then be confirmed by molecular methods (PCR/sequencing or qPCR), which reliably separate N. guarroi from the other Nannizziopsiaceae and from opportunistic molds [6].

Differential diagnoses to exclude include simple dysecdysis, thermal burns from basking equipment, traumatic or bacterial ulcerative dermatitis (including septicaemic cutaneous ulcerative disease), and — where oral or facial lesions predominate — ulcerative stomatitis / mouth rot. Assess for concurrent husbandry-driven disease such as metabolic bone disease and secondary respiratory infection, since husbandry deficits both predispose to and complicate YFD.

Treatment

Treatment is multimodal: systemic antifungal drug therapy + surgical debridement of devitalised tissue + husbandry correction + strict biosecurity. Plan for long courses — weeks to months — and confirm cure with repeat culture, histopathology, and PCR rather than visual resolution alone.

Voriconazole is a well-supported first choice. In the controlled study by Van Waeyenberghe et al., voriconazole 10 mg/kg PO q24h achieved plasma concentrations above the MIC of CANV isolates and cleared infection over several weeks (mean roughly 47 days), with 6 of 7 treated dragons surviving [3]. In the same trial itraconazole 5 mg/kg PO q24h performed markedly worse — only 2 of 7 survived — which is why voriconazole is preferred over itraconazole in this species [3].

Terbinafine is the other strong option and has the lowest MICs against N. guarroi of the drugs tested (15–30 ng/mL, versus 60–250 ng/mL for voriconazole and 125–2,000 ng/mL for itraconazole) [4]. Single-dose pharmacokinetics by McEntire et al. support terbinafine 20 mg/kg PO q24–48h, a regimen that kept plasma concentrations above 30 ng/mL for more than 24 hours [4]. A published case report cured a bearded dragon of culture-, histopathology-, and qPCR-confirmed N. guarroi using systemic terbinafine after voriconazole had failed clinically, combined with weekly enclosure disinfection using sodium hypochlorite [7]. Nebulised terbinafine is established for ophidiomycosis in snakes and is a reasonable adjunct where oral dosing is difficult, though bearded-dragon-specific nebulisation pharmacokinetics are lacking [4].

Itraconazole remains a historical option but is second-line: variable absorption by formulation and dose-dependent hepatotoxicity (elevated AST) reported in bearded dragons argue for caution and biochemistry monitoring if it is used [8]. Whatever the drug, debride crusts and necrotic tissue surgically to lower fungal burden and improve drug penetration [2].

Husbandry correction and biosecurity are not optional. Optimise the temperature gradient, basking and UVB provision, humidity, and enclosure hygiene, because husbandry stress predisposes to invasive disease. Because N. guarroi is contagious and contaminates the environment before lesions appear, isolate every affected or exposed animal, use dedicated equipment, and disinfect enclosures thoroughly (sodium hypochlorite is effective); quarantine new acquisitions and screen them before introduction to a collection [5].

Prognosis

Prognosis depends on depth of invasion. Superficial, early disease treated with an appropriate systemic antifungal and debridement carries a fair-to-good prognosis — 6 of 7 dragons cleared infection on voriconazole in the controlled trial, and terbinafine has produced documented cures [3][7]. Once infection invades subcutis, bone, or viscera the outlook becomes guarded to poor: deep and disseminated nannizziomycosis has high fatality even with therapy [2]. Relapse is possible, so treat to microbiological cure (negative culture/PCR), maintain biosecurity throughout, and re-examine after therapy ends [5].

Frequently Asked Questions